RARA CRAFT DATABASE for FDA Medical Devices
PMAP030054S284

FDA DEVICE FACTS

QUADRA ASSURA / UNIFY ASSURA FAMILY OF CRT-D'S

ABBOTT MEDICAL

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEAugust 27, 2015PRODUCT CODENIK

Indications for use

Implantation of a single-chamber pulse generator or dual-chamber pulse generator is indicated in one or more of the following permanent conditions: x Syncope x Presyncope x Fatigue x Disorientation due to arrhythmia/bradycardia x Or combination of those symptoms

Rate-Modulated Pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-Chamber Pacing (Dual-chamber pulse generators) is indicated for those patients exhibiting: x Sick sinus syndrome x Chronic, symptomatic second- and third-degree AV block x Recurrent Adams-Stokes syndrome x Symptomatic bilateral bundle branch block when tachyarrhythmia and other causes have been ruled out. Atrial Pacing is indicated for patients with sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular Pacing is indicated for patients with significant bradycardia and: x Normal sinus rhythm with only rare episodes of A-V block or sinus arrest x Chronic atrial fibrillation x Severe physical disability

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026